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Poster Session II S287patients, donor hematopoiesis is accounted for by one unit, although
the mechanisms of unit dominance are not established. Cord blood
NK cells are predominantly of a mature phenotype, with cytotoxic
activity following IL-2 stimulation comparable to peripheral blood
NK cells, but with higher proliferation capacity. We, therefore, hy-
pothesized that NK cells may determine unit dominance following
DCBT. We examined KIR haplotypes of each unit, and the unit-
unit and unit-recipient KIR-HLA interactions in 83 DCBT recipi-
ents transplanted at MSKCC between October 2005 and July 2010
for hematological malignancies. Median age of patients was 35.6
years (0.9-64.6). Patients received myeloablative (n 5 65) or non-
myeloablative (n 5 18) conditioning, and immunosuppression with
a calcineurin inhibitor and mycophenolate mofetil. Chi-square test
was used to examine the frequency distributions differences of spe-
cific KIR haplotypes and individual activating KIR between the pre-
dominating and the non-engrafting units. It was also used to test
equal frequency distributions of inhibitory KIR-mediatedmissing li-
gand ormissing self. Group B-haplotypes (34.9% vs. 41.4%, p5 0.2)
were not associated with a higher likelihood of unit dominance. Sim-
ilarly, none of the individual activating KIR showed any association
with unit dominance. The majority of unit pairs either had no KIR-
HLA combinations predictive of NK alloreactivity (n 5 20), or had
NK alloreactivity predicted to occur in a bidirectional manner (n 5
35). Results from unit-unit interaction analyses showed that units
missing KIR ligand (16/29 vs 13/29, p5 0.71), or lacking class I de-
terminants present in the second unit (12/18 vs 6/18, p 5 0.23), did
not show a lower rate of engraftment. For unit-recipient interac-
tions, cord blood units did not have a higher likelihood of engraft-
ment even if the patient was missing ligand for the unit inhibitory
KIR (2/7 vs. 5/7, p 5 0.45), or lacked class I determinants present
in the unit (7/16 vs. 9/16 p 5 0.80). Results from recipient-unit in-
teraction analyses revealed that units missing KIR ligand (12/25 vs.
13/25, p5 1.00) or lacking class I determinants present in the recip-
ient (9/19 vs. 10/19, p 5 1.00) did not show a lower rate of engraft-
ment. In this cohort of DUCBT, we could not demonstrate a role for
KIR-HLA genotypes or KIR haplotypes in predicting cord unit
predominance.368
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Allogeneic hematopoietic stem cell transplantation(HSCT) must
serve as a platform for adoptive cellular immunotherapy to fully ex-
ploit graft versus leukemia effects. We have developed a 4-log ex-
vivo T lymphocyte depleted HSCT with minimal graft versus host
disease (GvHD) prophylaxis followed by elective donor lymphocyte
infusion at day 90. A lymphodepleted environmentwithout immuno-
suppressionwould favor homeostatic expansion of adoptively infused
cells in future protocols. 39 patients with hematologic malignancies
underwent allogeneic HSCT with a graft from their HLA-identical
siblings. The median age was 41 years (range 16-68), 17/39 were
males. Transplant indications were AML(18), ALL(8), acute biphe-
notypic leukemia(1), MDS(7), NHL/CLL(3), CMMoL(1) and
CML(1). 50% were standard risk and 50% were at high risk for re-
lapse. Subjects received myeloablative conditioning with cyclophos-
phamide (60 mg/kg/dose x 2), fludarabine (25 mg/m2/dose x 5) and
total body irradiation (12 Gy in 8 fractions, lungs shielded to 6Gy).
Ten subjects,whowere 55 years of age or older, received 4Gydivided
in 8 fractions without lung shielding. G-CSF mobilized peripheral
blood grafts from the donor were CD34+ selected (Miltenyi Clini-
Macs), with infusion of a target CD34+ dose of 6x10e6/kg and a fixed
CD3+ dose of 5x10e4/kg. Low-dose cyclosporine (100-200ng/mL)
till day 21 was the only GVHD prophylaxis. Delayed lymphocyte
add back (5x10e6CD3+/kg) was given at day 90 if patients had no sig-
nificant GVHD. CD3+ and myeloid chimerism analyses were per-
formed with early lymphocyte add-back in cases with fallingchimerism. Day 200 overall survival (the primary study endpoint)
was 84%. One patient, who was postpartum, failed to engraft and re-
quired a second transplant. 37/39 subjects achieved complete
(. 95%) donor myeloid chimerism by day14. The median times to
complete donor CD3+ chimerism were day30 for 12 Gy subjects
and . 6 months for 4 Gy subjects (Mann Whitney test, p 5 0.004).
The incidence of acute GVHD grade II, III and IV were 23%,
2.9% and 0%, respectively. The incidence of chronic GVHD was
34%. At a median follow up of 3.7 years, Kaplan-Meier estimates
of relapse, nonrelapse mortality and overall survival were 32%,
31% and 46% respectively without any significant difference based
on conditioning intensity. In conclusion, conditioning intensity in-
fluences the rapidity of complete donor CD3+ chimerism in trans-
plants utilizing this platform for adoptive cellular immunotherapy.369
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In leukemia patients, peripheral blood stem cells (PBSC) have re-
placed bone marrow (BM) as stem cell source. No study has shown
any benefit using PBSC versus BM in matched unrelated donor
(MUD) transplantation. We therefore compared PBSC and BM in
MUD recipients with acute myeloid leukemia (AML).
Between 1997 and 2008, 760 patients received BM and 1,502
PBSC from a MUD. The PBSC group were older age (p\ 0.01),
had more advanced disease (p\0.0001), received less total body ir-
radiation (p\0.0001), and more antithymocyte globulin (p5 0.01).
Recovery of neutrophils and platelets was faster with PBSC (p\
0.0001). Acute GVHD was similar, but chronic GVHD was in-
creased in the PBSC group (HR 1.29, p 5 0.02). Non-relapse mor-
tality (NRM), relapse and leukemia-free survival (LFS) did not differ
between the two groups, in AML patients in remission. However, in
patients with advanced AML, NRM was decreased (HR 0.61, p 5
0.02) and LFS was improved (HR 1.49, p 5 0.002) using PBSC.
At 3 years, LFS for all patients, regardless of remission status, was
4161% for both groups.
PBSC compared to BM in MUD transplants in AML resulted in:
faster neutrophil and platelet recovery, not statistically different
acute GVHD, increased chronic GVHD and same rates of LFS in
remission patients. In advanced AML, the PBSC group had
decreased NRM and improved LFS.370
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Achieving engraftment of T cell depleted BMT under reduced in-
tensity conditioning (RIC) remains a major challenge. Recently, we
demonstrated that anti 3rd-party CD8 T cells with ex-vivo induced
central memory phenotype (Tcm) can enhance BM engraftment
